| Characteristic | 15 days mortality | 30 days mortality | Overall, N = 6041 | ||||||
| No N = 4461 | Yes N = 1581 |
| p-value2 | No N = 4331 | Yes N = 1711 |
| p-value2 | ||
| Age (Year) | 52 (41-64) | 63 (47-73) |
| <0.001 | 51 (40-64) | 63 (47-73) |
| <0.001 | 54 (41-68) |
| Age classes (Year) |
|
|
| <0.001 |
|
|
| <0.001 |
|
| <20 | 6 (100.0) | 0 (0.0) |
|
| 6 (100.0) | 0 (0.0) |
|
| 6 |
| 20 - 39 | 97 (79.5) | 25 (20.5) |
|
| 96 (78.7) | 26 (21.3) |
|
| 122 |
| 40 - 59 | 186 (82.3) | 40 (17.7) |
|
| 180 (79.6) | 46 (20.4) |
|
| 226 |
| 60 - 79 | 136 (65.4) | 72 (34.6) |
|
| 132 (63.5) | 76 (36.5) |
|
| 208 |
| ≥80 | 21 (50.0) | 21 (50.0) |
|
| 19 (45.2) | 23 (54.8) |
|
| 42 |
| Sex |
|
|
| 0.711 |
|
|
| 0.786 |
|
| Female | 221 (73.2) | 81 (26.8) |
|
| 215 (71.2) | 87 (28.8) |
|
| 302 |
| Male | 225 (74.5) | 77 (25.5) |
|
| 218 (72.2) | 84 (27.8) |
|
| 302 |
| Clinical severity at admission |
|
| <0.001 |
|
|
| <0.001 |
| |
| Asymptomatic/Mild | 125 (98.4) | 2 (1.6) |
|
| 125 (98.4) | 2 (1.6) |
|
| 127 |
| Moderate | 141 (90.4) | 15 (9.6) |
|
| 139 (89.1) | 17 (10.9) |
|
| 156 |
| Severe | 159 (64.1) | 89 (35.9) |
|
| 148 (59.7) | 100 (40.3) |
|
| 248 |
| Critical | 21 (28.8) | 52 (71.2) |
|
| 21 (28.8) | 52 (71.2) |
|
| 73 |
| Hospitalization in the intensive care unit |
|
| <0.001 |
|
|
| <0.001 |
| |
| No | 219 (92.4) | 18 (7.6) |
|
| 218 (92.0) | 19 (8.0) |
|
| 238 |
| Yes | 227 (61.9) | 140 (38.1) |
|
| 215 (58.6) | 152 (41.4) |
|
| 367 |
| At least one complication |
|
| 0.089 |
|
|
| 0.124 |
| |
| No | 403 (75.0) | 135 (25.0) |
|
| 391 (72,7) | 147 (27.3) |
|
| 538 |
| Yes | 43 (65.2) | 23 (34.8) |
|
| 42 (63.6) | 24 (36.4) |
|
| 66 |
| Complete COVID-19 vaccination |
|
| 0.003 |
|
|
| <0.001 |
| |
| No | 396 (72.1) | 153 (27.9) |
|
| 383 (69.8) | 166 (30.2) |
|
| 549 |
| Yes | 50 (90.9) | 5 (9.1) |
|
| 50 (90.9) | 5 (9.1) |
|
| 55 |